Singapore markets closed

NVO Sep 2024 180.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
55.700.00 (0.00%)
As of 11:50AM EDT. Market open.
Full screen
Previous close55.70
Open54.70
Bid54.60
Ask54.85
Strike180.00
Expiry date2024-09-20
Day's range54.70 - 55.70
Contract rangeN/A
Volume2
Open interestN/A
  • GlobeNewswire

    Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association

    FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes1SELECT cardiovascular outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity and established cardiovascular disease, without diabetes2STEP HFpEF trial programme data evaluating efficacy and safety of once-weekly semaglutide 2.4 mg in people with obesity-related heart failure with preserved ejection fraction (HFpEF), w

  • Barrons.com

    New Weight-Loss Drugs and Devices Are Coming This Week

    Weight-loss breakthroughs all emerged from diabetes treatment. Meetings such as the coming American Diabetes Association are increasingly dominated by news on obesity drugs.

  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiat